Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cidara Therapeutics (CDTX) EBITDA Margin: 2018-2025

Historic EBITDA Margin for Cidara Therapeutics (CDTX) over the last 4 years, with Mar 2025 value amounting to 21,345.45%.

  • Cidara Therapeutics' EBITDA Margin rose 2240671.00% to 21,345.45% in Q1 2025 from the same period last year, while for Mar 2025 it was -1,491.90%, marking a year-over-year decrease of 134179.00%. This contributed to the annual value of -13,319.76% for FY2024, which is 1322128.00% down from last year.
  • Latest data reveals that Cidara Therapeutics reported EBITDA Margin of 21,345.45% as of Q1 2025, which was up 170.68% from -30,201.66% recorded in Q2 2024.
  • In the past 5 years, Cidara Therapeutics' EBITDA Margin registered a high of 21,345.45% during Q1 2025, and its lowest value of -30,201.66% during Q2 2024.
  • Moreover, its 3-year median value for EBITDA Margin was -130.10% (2023), whereas its average is -1,475.59%.
  • In the last 5 years, Cidara Therapeutics' EBITDA Margin slumped by 2,993,399bps in 2024 and then soared by 2,240,671bps in 2025.
  • Cidara Therapeutics' EBITDA Margin (Quarterly) stood at -600.11% in 2021, then spiked by 46,705bps to -133.06% in 2022, then soared by 10,411bps to -28.95% in 2023, then tumbled by 2,993,399bps to -30,201.66% in 2024, then skyrocketed by 2,240,671bps to 21,345.45% in 2025.
  • Its last three reported values are 21,345.45% in Q1 2025, -30,201.66% for Q2 2024, and -1,061.25% during Q1 2024.